
Keywords: Urolithins; Prostate cancer; Interactions; Ellagitannins gut metabolites; ADT; androgen deprivation therapy; AR; androgen receptor; bic; bicalutamide; CI; combination index; DHT; dihydrotestosterone; GnRH; gonadotropin-releasing hormone; PSA; prostate spe